Non-invasive glucose sensors

Grader A: miss

As of February 2024 the FDA had authorized no non-invasive glucose device and warned against wearables claiming it; CGMs that took the market are minimally invasive. Early CE-marked attempts (e.g. GlucoTrack) did not reach routine use. No real use by 2025.

Test: D37 health: share of relevant patients, providers or procedures using it by 2022 (hit >=5%; partial <5% real use by 2022 or 5% in 2023-2025; miss no real use by 2025); relevant: people with diabetes

• Do Not Use Smartwatches or Smart Rings to Measure Blood Glucose Levels: FDA Safety Communication (2024-02-21): FDA has not authorized any non-invasive glucose smartwatch or ring

Grader B: miss

No non-invasive glucose monitor is FDA-authorised; in Feb 2024 FDA warned against smartwatches and rings claiming it. Diabetes care moved to minimally invasive CGMs (filament under the skin), which do not meet the label. A few CE-marked devices (e.g. GlucoTrack) never reached routine use, and GlucoTrack pivoted to an implantable sensor.

Test: D37 health: >=5% of glucose-monitoring diabetics use it by 2022 = hit; real use below 5% = partial; no real use by 2025 = miss.

• Do Not Use Smartwatches or Smart Rings to Measure Blood Glucose Levels: FDA Safety Communication (2024-02-21): FDA has not authorised any smartwatch or smart ring that measures blood glucose on its own.